The study investigates the efficacy of a sulforaphane-enriched supplement in modulating NRF2 to mitigate ozone-induced airway inflammation. Given the increasing prevalence of respiratory conditions and the growing interest in nutraceuticals, this research could position sulforaphane as a viable adjunct therapy in respiratory health. The findings may attract attention from pharmaceutical companies focusing on respiratory diseases and environmental health, as well as from dietary supplement manufacturers. Competitive landscape includes existing anti-inflammatory agents and emerging nutraceuticals targeting oxidative stress. Diligence should focus on regulatory pathways for dietary supplements versus pharmaceuticals, as well as potential partnerships with environmental health organizations.